Zhaoyi Liu

Zhaoyi Liu

Auto-generated profile, based on publicly available information

Zhaoyi Liu

Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair, Tianjin General Surgery Institute, Tianjin, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WSWenbin Song
Wenbin Song
ZLZhaoyi Liu
Zhaoyi Liu
CSCangchang Shi
Cangchang Shi
GWGuixin Wang
Guixin Wang
LHLong He
Long He
XHXianghui He
Xianghui He
Background: The incidence of thyroid cancer has been increasing in recent years, with papillary thyroid carcinoma (PTC) accounting for the majority of cases. Accumulating studies have demonstrated that S100A10 acts as an oncogene in the progression of various malignancies. However, the function and specific mechanisms of S100A10 in thyroid cancer remain poorly defined. Methods: Single-cell RNA sequencing data of PTC from public databases were analyzed to screen differentially expressed genes (DEGs), among which S100A10 emerged as a potential biomarker associated with PTC metastasis and prognosis. The expression of S100A10 in tissues and cell lines were validated by RT-qPCR and western blot. Protein-protein interactions were confirmed using mass spectrometry analysis and co-immunoprecipitation. The subcellular localization of the protein was determined by immunofluorescence. Stable PTC cell lines overexpressing S100A10 were constructed and followed by transwell assays, wound-healing assays, and western blot for EMT capability detection. Results: S100A10 was found to play essential roles in tumor metastasis and was associated with unfavorable prognosis in patients with PTC. S100A10 was expressed higher in both PTC tissues and cells. Furthermore, both in vitro and in vivo experiments confirmed that S100A10 activates the PI3K/AKT signaling and promotes EMT in PTC cells, enhancing the invasive capabilities of tumors. S100A10 could interact with both RAN and EGFR intracellularly, forming a RAN-S100A10-EGFR regulatory axis. Finally, several potential drugs targeting S100A10 were identified for further in-depth research. Conclusion: These findings clarify the role of S100A10 and RAN in PTC progression and highlight their potential as therapeutic targets, linking EMT with PI3K/AKT signaling.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
THTao Hu
Tao Hu
WSWenbin Song
Wenbin Song
ZLZhaoyi Liu
Zhaoyi Liu
CSCangchang Shi
Cangchang Shi
XHXiaoyan Hu
Xiaoyan Hu
YLYingxi Li
Yingxi Li
Background: Colorectal cancer (CRC) is a common and lethal disease worldwide. The chromobox (CBX) protein family, integral to the Polycomb repressive complex 1 (PRC1), plays a crucial role in epigenetic regulation and the progression of cancer. The expression profiles, clinical importance, and roles of various CBX family members in CRC remain unclear, especially concerning nonepigenetic functions and roles in the tumor microenvironment. Methods: The transcriptional profiles of the entire CBX family, consisting of eight members, were systematically analyzed using multiple public databases. Genomic alterations, prognostic data, and GSEA identified CBX3 as an important oncogenic gene. To explore CBX3 expression patterns and their association with immune cell infiltration in the tumor microenvironment, single‐cell RNA sequencing was employed. Through experimental validation, cell proliferation, migration, apoptosis, and cell cycle analysis, the oncogenic role of CBX3 was confirmed. Experiments involving coimmunoprecipitation and immunofluorescence colocalization were performed to confirm protein–protein interactions and subcellular localization of the protein. The screening of the CMap was executed to find potential therapeutic compounds, sorted by CBX3 expression levels. Results: The integrated analysis revealed a complicated expression pattern of CBX family members in CRC, with notable increases in CBX2, CBX3, CBX4, and CBX8, whereas CBX6 and CBX7 were decreased in tumor tissues. The prognostic analysis revealed that higher levels of CBX3, CBX4, CBX6, CBX7, and CBX8 were connected to lower overall survival rates, whereas increased CBX5 expression was associated with improved prognosis. Among all members, CBX3 was noted for having the highest frequency of alterations and the most frequent copy number gain, establishing it as a leading oncogenic driver. Single‐cell analysis showed that CBX3 expression was predominantly found in malignant cells, and higher CBX3 levels were associated with increased infiltration of immunosuppressive regulatory T cells. CMap screening revealed that epidermal growth factor receptor (EGFR) inhibitors were the most significantly enriched compounds in the high CBX3 expression group. In vitro, reducing CBX3 expression decreased cell proliferation and migration, promoted apoptosis, and caused G2/M phase arrest in CRC cells. CBX3 interacts with EGFR, activating the PI3K/AKT signaling pathway and promoting epithelial–mesenchymal transition (EMT). Conclusion: CBX3 was identified as a crucial oncogenic factor in CRC, enhancing tumor development through its interaction with EGFR and activation of the PI3K/AKT signaling pathway. CBX3 could be an indicator for predicting patient outcomes and their response to EGFR inhibitor treatment, which serves as a promising biomarker and a potential therapeutic target to advance precision medicine.